
Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System.

In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Modern Retina spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

A hope for reducing treatment burden for wet age-related macular degeneration with a sustained-release vorolanib intravitreal insert

Retinal imaging and the future of early Alzheimer diagnosis.

Phase 1/2 interim results highlight real-world functional enhancements in patients with severe LCA5-related Leber congenital amaurosis.

Innovative assistive devices empower patients with central vision loss to regain independence and enhance daily activities, transforming their quality of life.

Dr. Gonzalez shares 126-week topline results from the REMAIN study, assessing optogenetic therapy MCO-010 (Nanoscope Therapeutics).


Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease connections using advanced OCT technology.

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025.

Breakthrough suprachoroidal injection technique offers promising treatment for diabetic retinopathy, reducing visual threatening complications from 37% to 4% with minimal inflammation and office-based procedure.

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement.

Ophthalmologist Dilraj Grewal explores cutting-edge clinical trials for uveitis treatment, highlighting new targeted therapies that aim to control inflammation and macular edema with fewer steroid-related side effects.

Lexitas Pharma Services' CMO discusses groundbreaking ophthalmology conference, emphasizing innovative clinical trials, emerging treatments for eye diseases, and the potential for transformative patient care strategies.

Focused on corneal disease research, Deng has been part of ARVO in various roles for more than 20 years.

The cross sector initiative that intends to drive a shift from reactive to proactive health care by leveraging ocular data through the means of oculomics.

Retina specialist Priya Vakharia, MD, reveals promising ANX007 trial results, showing potential to prevent vision loss in geographic atrophy.

Ophthalmologist Tarek Hassan introduces new surgical approach for proliferative vitreoretinopathy, using precise small retinotomies instead of extensive retinal removal to improve patient outcomes.

Ultra-wide field imaging shows nonperfusion and leakage independently predict diabetic retinopathy progression, suggesting earlier treatment with anti-VEGF or photocoagulation may prevent complications.

Kriya Therapeutics presented preclinical data on its gene therapy candidate for the treatment of geographic atrophy.

Ashvattha Therapeutics announced positive interim phase 2 results for migaldendranib for the treatment of AMD and DME.

Four-year study shows faricimab in treat-and-extend regimen maintains vision for diabetic macular edema patients with significantly fewer injections over time.

SYL1801 is a treatment for neovascular macular degeneration administered via eye drops.

Kapil Mishra, MD, discusses an overview of radiation retinopathy and its challenges in treating uveal melanoma from his presentation "Radiation Retinopathy: Future Strategies,"

Duke professor Sharon Fekrat, MD, discusses AI-driven ophthalmology with smartphone diagnostics and robotic procedures, emphasizing global collaboration and innovative medical research.

Palatin Technologies reveals groundbreaking preclinical results on melanocortin agonists, showcasing their potential to combat diabetic retinopathy and preserve vision.

Alfredo Sadun, MD, PhD, details a fascinating outcome from a gene therapy in development for Leber hereditary optic neuropathy.

The company shared results from the AAVB-081 clinical program and AAVB-039 preclinical program at ARVO.